• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Challenges in analyzing clinical trials testing Bruton tyrosine-kinase-inhibitora in chronic lymphocytic leukaemia.

作者信息

Shao Yingqi, Kay Neil E, Gale Robert Peter, Liang Yang

机构信息

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.

Division of Hematology, and Department of Immunology, Mayo Clinic, Rochester, MN, USA.

出版信息

Leukemia. 2024 Jul;38(7):1469-1473. doi: 10.1038/s41375-024-02294-8. Epub 2024 Jun 1.

DOI:10.1038/s41375-024-02294-8
PMID:38824147
Abstract
摘要

相似文献

1
Challenges in analyzing clinical trials testing Bruton tyrosine-kinase-inhibitora in chronic lymphocytic leukaemia.分析慢性淋巴细胞白血病中布鲁顿酪氨酸激酶抑制剂临床试验的挑战。
Leukemia. 2024 Jul;38(7):1469-1473. doi: 10.1038/s41375-024-02294-8. Epub 2024 Jun 1.
2
Next-Generation Bruton Tyrosine Kinase Inhibitors.下一代布鲁顿酪氨酸激酶抑制剂
J Clin Oncol. 2020 Sep 1;38(25):2937-2940. doi: 10.1200/JCO.20.01594. Epub 2020 Jul 16.
3
Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.新兴布鲁顿酪氨酸激酶抑制剂治疗慢性淋巴细胞白血病：伊布替尼更进一步。
Expert Opin Emerg Drugs. 2020 Mar;25(1):25-35. doi: 10.1080/14728214.2020.1724282. Epub 2020 Feb 6.
4
Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.布鲁顿酪氨酸激酶抑制剂在慢性淋巴细胞白血病合并新型冠状病毒肺炎患者中的保护作用
Br J Haematol. 2020 Jul;190(2):e73-e76. doi: 10.1111/bjh.16863. Epub 2020 Jun 4.
5
Chronic lymphocytic leukaemia-associated insect bite-like reaction responding to ibrutinib, an immunomodulatory Bruton tyrosine kinase inhibitor.慢性淋巴细胞白血病相关的昆虫叮咬样反应对免疫调节性布鲁顿酪氨酸激酶抑制剂依鲁替尼有反应。
Clin Exp Dermatol. 2021 Dec;46(8):1569-1571. doi: 10.1111/ced.14761. Epub 2021 Jun 22.
6
Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Beyond Ibrutinib.布鲁顿酪氨酸激酶抑制剂在慢性淋巴细胞白血病中的应用：超越伊布替尼。
Hematol Oncol Clin North Am. 2021 Aug;35(4):761-773. doi: 10.1016/j.hoc.2021.03.006. Epub 2021 May 28.
7
BTK Inhibitors and Chemoimmunotherapy for CLL.布鲁顿酪氨酸激酶抑制剂与慢性淋巴细胞白血病的化学免疫疗法
Clin Lymphoma Myeloma Leuk. 2020 Sep;20 Suppl 1:S22-S24. doi: 10.1016/S2152-2650(20)30449-3.
8
Severe arthritic syndrome due to ibrutinib use for chronic lymphocytic leukemia.因使用依鲁替尼治疗慢性淋巴细胞白血病导致的严重关节炎综合征。
J Oncol Pharm Pract. 2019 Jun;25(4):1003-1005. doi: 10.1177/1078155218772327. Epub 2018 May 3.
9
BTK Inhibitors in Chronic Lymphocytic Leukemia.布鲁顿酪氨酸激酶抑制剂在慢性淋巴细胞白血病中的应用。
Curr Hematol Malig Rep. 2021 Oct;16(5):422-432. doi: 10.1007/s11899-021-00645-1. Epub 2021 Oct 2.
10
US Food and Drug Administration approvals for Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: Potential inefficiencies in trial design and evidence generation.美国食品和药物管理局批准用于慢性淋巴细胞白血病患者的布鲁顿酪氨酸激酶抑制剂：临床试验设计和证据生成中的潜在效率低下。
Cancer. 2020 Oct 1;126(19):4270-4272. doi: 10.1002/cncr.33058. Epub 2020 Jul 9.

本文引用的文献

1
Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials.无进展生存期的估计受特定删失规则的影响：对癌症随机试验中 PFS 作为终点的影响。
Eur J Cancer. 2024 May;202:114022. doi: 10.1016/j.ejca.2024.114022. Epub 2024 Mar 20.
2
Challenging the Value of Minimal Residual Disease in Predicting Outcome of Patients With Chronic Lymphocytic Leukemia.质疑微小残留病在预测慢性淋巴细胞白血病患者预后中的价值。
J Clin Oncol. 2023 Jul 20;41(21):3676-3678. doi: 10.1200/JCO.23.00619. Epub 2023 Jun 6.
3
Incidence of Primary End Point Changes Among Active Cancer Phase 3 Randomized Clinical Trials.
活性癌症阶段 3 随机临床试验主要终点变化的发生率。
JAMA Netw Open. 2023 May 1;6(5):e2313819. doi: 10.1001/jamanetworkopen.2023.13819.
4
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.伊布替尼联合利妥昔单抗与氟达拉滨、环磷酰胺和利妥昔单抗治疗初治慢性淋巴细胞白血病患者（FLAIR）：一项多中心、开放标签、随机、3 期临床试验的中期分析。
Lancet Oncol. 2023 May;24(5):535-552. doi: 10.1016/S1470-2045(23)00144-4.
5
Zanubrutinib in Chronic Lymphocytic Leukemia.
N Engl J Med. 2023 May 4;388(18):1720. doi: 10.1056/NEJMc2302350.
6
Assessment of Median and Mean Survival Time in Cancer Clinical Trials.癌症临床试验中中位生存期和平均生存期的评估。
JAMA Netw Open. 2023 Apr 3;6(4):e236498. doi: 10.1001/jamanetworkopen.2023.6498.
7
Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival.不可调和的差异：缓解率、无进展生存期和总生存期之间的脱节
J Clin Oncol. 2023 May 20;41(15):2706-2712. doi: 10.1200/JCO.23.00225. Epub 2023 Mar 17.
8
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.泽布替尼或伊布替尼用于复发或难治性慢性淋巴细胞白血病
N Engl J Med. 2023 Jan 26;388(4):319-332. doi: 10.1056/NEJMoa2211582. Epub 2022 Dec 13.
9
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.伊布替尼-利妥昔单抗与化疗免疫治疗慢性淋巴细胞白血病的长期疗效：E1912 试验的更新结果。
Blood. 2022 Jul 14;140(2):112-120. doi: 10.1182/blood.2021014960.
10
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.RESONATE-2 研究的 8 年随访结果：伊布替尼一线治疗慢性淋巴细胞白血病患者。
Blood Adv. 2022 Jun 14;6(11):3440-3450. doi: 10.1182/bloodadvances.2021006434.